Natural IVY Leaf Extract, Anti-Inflammatory Expectorant

• Customization: Available
• Certification: ISO
• Assay Method: HPLC-MS, HPLC
• Model NO.: NY112
• Application Form: Softgels, Tinctures, Liquids, Drops
• Application: Food, Health Care Products
• State: Powder
• Extract Source: Lvy Leaf
• Transport Package: 25kg/Drum
• Specification: 98%
• Trademark: Nutrayours/ OEM
• Origin: China
• HS Code: 1302119700
• Production Capacity: 3000kg/Year

Product Description

About this item

• 100% NATURAL PRODUCT: No artificial colors or flavors
• Verified herb identity, confirmed highest quality of raw herb and the extract
• Best natural sources of herbs and raw materials: Every vendor is carefully picked to meet our high standards
• Third-party lab tested, pure Ivy leaf extract

•

Ivy leaf is a traditional perennial edible herb used as an anti-inflammatory agent for respiratory disorders.

•

The plant significantly reduced the serum oxidative stress biomarkers and inflammatory cytokines in the in-vivo acute lung inflammation model induced by LPS.

•

Also, it had antimicrobial activity.

•

Phenolics not saponins are responsible for the activity of the plant.

 

Function and efficacy

Ivy leaf extract contains saponins which are believed to have expectorant properties. In vitro studies of ivy mono-preparations show evidence of potential antispasmodic and bronchodilating activity, anti-inflammatory effects, and antitussive properties. This review is an update of our systematic review published in 2011 which found that evidence for the efficacy of ivy leaf extract in acute cough was inconclusive due to lack of methodologically robust data . The objective of this review was to identify and evaluate new data regarding the effectiveness and tolerability of ivy leaf in the symptomatic treatment of acute bronchitis associated with acute URTIs in children and adults.

 

Hedera helix L. (family Araliaceae) is classified as a conventional plant used as a medicinal product in the cure and prevention of upper respiratory tract inflammation and infection due to its secretolytic and broncholytic effects. Our research was conducted to authenticate the anti-inflammatory effect of ivy leaves extract in the prevention of acute lung injury (ALI) caused by intranasal administration of lipopolysaccharides (LPS). In-vitro antimicrobial, anti-inflammatory, and anti-oxidant were evaluated, in addition to the in-vivo acute lung inflammation model induced by LPS in mice. The animals were divided into seven groups randomly (each group containing 10 mice): control negative (saline only), control positive (LPS group), standard (Dex amethasone 2 mg/kg), ethanolic ivy leaves extract (EIE, 100 mg/kg), ethanolic ivy leaves extract (EIE, 200 mg/kg), saponin rich fraction (SRF, 100 mg/kg) and phenolic rich fraction (PRF, 100 mg/kg). Right lungs were homogenized to determine the levels of SOD, MDA, catalase, IL-10, TNF-α, NO, IL-1β, IL-6, PGE2, and MPO. Left lungs were excised for histopathology and histomorphometry. Immunohistochemistry of Cox-2 and TNF-α levels were measured. Additionally, Western blotting was used to determine the levels of phosphorylated MAPK. Also, the ethanolic extract was also standardized through HPLC analysis for its content of rutin.The data showed that the oral supplementation with EIE, 200 mg/kg significantly (P < 0.05) decreased the pro-inflammatory mediators, and oxidative stress biomarkers induced by LPS. Interestingly, the phenolics showed promising activity, therefore they are responsible for the action. In conclusion, the standardized ivy leaf extract could be advised for acute lung injury for its antimicrobial, anti-oxidant, and anti-inflammatory activities.

 

The ivy leaves as known in English or Hedera helix L. in Latin (Araliaceae), growing in most of the territory of Europe and in the western regions of Ukraine, are used in folklore medicine for numerous conditions, including respiratory disorders with expectorant activity to treat cough, cold and acute or chronic bronchial disorders (bronchitis) (Holzinger and Chenot, 2011). 

 

About us

* The statements in this section have not been evaluated by the FDA or EFSA.
 

References

    1.Holzinger F, Chenot JF.Evid Based Complement Alternat Med. 2011;2011:382789. doi: 10.1155/2011/382789. Epub 2010 Oct 3.PMID: 20976077
    2.Kemmerich B, Eberhardt R, Stammer H.Arzneimittelforschung. 2006;56(9):652-60. doi: 10.1055/s-0031-1296767.PMID: 17063641 
    3.Schönknecht K, Fal AM, Mastalerz-Migas A, Joachimiak M, Doniec Z.Wiad Lek. 2017;70(6 pt 1):1026-1033.PMID: 29478973

    4.Lang C, Röttger-Lüer P, Staiger C.Planta Med. 2015 Aug;81(12-13):968-74. doi: 10.1055/s-0035-1545879. Epub 2015 Apr 15.PMID: 25875509
    5.Baharara H, Moghadam AT, Sahebkar A, Emami SA, Tayebi T, Mohammadpour AH.Adv Exp Med Biol. 2021;1328:361-376. doi: 10.1007/978-3-030-73234-9_23.PMID: 34981489